Tianshan Saussurea Functionalized Targeted Liposomes and Preparation Method and Application thereof

By using TPGS and ADH-1 peptide modification and encapsulation of coarse ragorin in Tianshan Snow Lotus functionalized liposomes, the problem of low epithelial stromal transformation and encapsulation rate of non-small cell lung cancer was solved, and high efficiency for lung cancer was achieved Targeted therapy reduces metastasis and side effects.

CN115120740BActive Publication Date: 2024-12-03CHENGDU MEDICAL COLLEGE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202210393616.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-15
Publication Date
2024-12-03
Estimated Expiration
2042-04-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit epithelial stromal transformation when treating non-small cell lung cancer, resulting in tumor metastasis and drug resistance problems. There are few studies on the anti-tumor active ingredients of Tianshan Xuelian and the target related to the target, and the encapsulation rate and drug loading volume are low. The problem.

Method used

Develop a targeted liposome, composed of TPGS and ADH-1 polypeptides, prepared by thin-film dispersion method, and modify ADH-1 polypeptide and TPGS on the surface of liposomes, which contains the active ingredient of Tianshan Snow Lotus, to improve the The encapsulation rate and drug loading volume of the drug enhance the targeting of tumor cells.

Benefits of technology

It significantly improved the therapeutic effect of Tianshan Snow Lotus active ingredient on epithelial stromal transformation of non-small cell lung cancer, enhanced the targeting of tumor cells, reduced metastasis and side effects, and provided a safe and feasible treatment plan for lung cancer metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention discloses a functionalized liposome of Saussurea involucrata and a preparation method and application thereof. The targeted liposome is composed of liposome, ADH‑1 and TPGS; ADH‑1 is connected to the amino group of the liposome. The present invention modifies the polypeptide ADH‑1 to the surface of the liposome, which can enhance the therapeutic effect of the active ingredients of Saussurea involucrata on epithelial-mesenchymal transition of non-small cell lung cancer, and has the effect of targeting tumor cells; TPGS is modified to the surface of the liposome to enhance the toxicity of the nanocarrier to tumor cells and improve the uptake of cells, and the most important thing is to increase the encapsulation rate and drug loading of ragweed with the help of TPGS. Rough-haired ragweed is encapsulated in liposomes to obtain a functionalized targeted nanocarrier, which can enable more drugs to reach the lesion site, greatly improve the chemotherapy effect, enhance the inhibitory effect of epithelial-mesenchymal transition, reduce metastasis and side effects, and is expected to provide a safe and feasible treatment plan for the treatment of lung cancer metastasis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and in particular relates to a functionalized targeted liposome of Saussurea involucrata and a preparation method and application thereof. Background Art

[0002] Non-small cell lung cancer is one of the most common malignant tumors in clinic. Patients generally have no obvious symptoms in the early stage. Tumor metastasis often occurs when the diagnosis is confirmed. The main sites of metastasis are the brain, bones, liver, adrenal glands, chest cavity and distant lymph nodes. Tumor metastasis is one of the main characteristics of advanced lung cancer and is the main cause of lung cancer treatment failure and patient death. A large number of studies have shown that epithelial-mesenchymal transition (EMT) plays a vital role in the primary invasion and secondary metastasis of lung cancer and is the main factor affecting the metastasis of lung tumors. In non-small cell lung cancer, epithelial-mesenchymal transition, metastasis and drug resistance are intertwined, which aggravates the disease and has a poor prognosis. Other studies have shown that the progression of non-small cell lung cancer is accompanied by epithelial-mesenchymal transition, which promotes the invasion and metastasis of tumor cells. At the same time, during the metastasis process, tumor cells can enter and spread through the blood and lymphatic system and metastasize to distant sites. On the contrary, inhibiting epithelial-mesenchymal transition can prevent tumor metastasis. Therefore, effectively inhibiting the epithelial-mesenchymal transition process will provide a new strategy for the treatment of lung cancer.

[0003] Saussurea involucrata Kar.et Kir. is a perennial herbaceous medicinal plant that grows in high altitude areas of Xinjiang, China. In traditional Chinese medicine theory, Saussurea involucrata has the effects of dispelling cold and dampness, promoting blood circulation, strengthening tendons and bones, and warming the kidney and promoting yang. It is used for symptoms such as lung cold cough, wind-cold dampness pain, rheumatoid arthritis and irregular menstruation. Modern pharmacological studies have shown that Saussurea involucrata has multiple pharmacological effects such as antioxidant, anti-fatigue, analgesic and anti-inflammatory, and anti-tumor (breast cancer, prostate cancer, etc.), most of which are closely related to its traditional uses. Among them, the anti-tumor effect of Saussurea involucrata has attracted widespread attention from researchers, but there are few studies on the correlation between its specific chemical components and anti-tumor activity, and the active ingredients, potential targets and related pathways of Saussurea involucrata have not been systematically explored.

[0004] The introduction of nanotechnology has opened up new prospects for targeted tumor treatment. In the treatment of lung cancer, nanotechnology plays an increasingly important role. At present, new drug delivery systems for the treatment of lung cancer are mainly divided into the following three categories: 1) lipid-based nanoparticles; 2) polymer nanoparticles; 3) inorganic nanoparticles. These advanced nano drug delivery systems have changed the original treatment methods, not only reducing toxic side effects, but also improving the bioavailability of drugs.

[0005] As the most successful nanocarrier in clinical transformation, liposomes have the following properties superior to other carrier materials: 1) highly increasing the efficacy and bioavailability of the encapsulated agent; 2) easily removed from the body through a simple metabolic pathway; 3) low toxicity, biocompatibility, and biodegradability; and 4) the ability to modify the surface and size, making them an attractive carrier for targeted and controlled drug delivery. Based on the above advantages, in this study, we constructed nanocarriers with liposomes as the core, aiming to develop a nano-drug delivery system with high efficacy, low side effects, and safety. Summary of the invention

[0006] An object of the present invention is to provide a targeted liposome.

[0007] The targeted liposome provided by the present invention is composed of TPGS-containing liposome and ADH-1 polypeptide; the ADH-1 is connected to the amino group of the liposome.

[0008] Wherein, the structural formula of the ADH-1 is as follows:

[0009]

[0010] The mass ratio of the ADH-1 to the TPGS-containing liposome is 1:10 to 25. The mass ratio here refers to the mass ratio of the input ADH-1 to the sum of the masses of lecithin, β-sitosterol, distearoylphosphatidylethanolamine-polyethylene glycol, distearoylphosphatidylethanolamine-polyethylene glycol-amino and TPGS used to prepare the TPGS-containing liposome.

[0011] The TPGS-containing liposome is prepared from lecithin, β-sitosterol, distearoylphosphatidylethanolamine-polyethylene glycol, distearoylphosphatidylethanolamine-polyethylene glycol-amino and TPGS (vitamin E polyethylene glycol succinate); wherein the amino group of the liposome is provided by distearoylphosphatidylethanolamine-polyethylene glycol-amino.

[0012] In the TPGS-containing liposome, the weight proportions of the raw materials are: 37.5-40 parts of lecithin, 10-12.5 parts of β-sitosterol, 1-2.5 parts of distearoylphosphatidylethanolamine-polyethylene glycol, 1-2.5 parts of distearoylphosphatidylethanolamine-polyethylene glycol-amino, and 3-4 parts of TPGS.

[0013] Preferably, the mass ratio of the phospholipid to β-sitosterol may be 3:1.

[0014] In the present invention, the distearoylphosphatidylethanolamine-polyethylene glycol can be specifically distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG 2000 );

[0015] In the present invention, the distearoylphosphatidylethanolamine-polyethylene glycol-amino can be specifically distearoylphosphatidylethanolamine-polyethylene glycol 2000-amino (DSPE-PEG 2000 -NH2).

[0016] The invention also provides a method for preparing the targeted liposome.

[0017] The method for preparing the targeted liposome provided by the present invention comprises the following steps:

[0018] 1) Preparation of TPGS-containing liposomes:

[0019] The lecithin, the β-sitosterol, the distearoylphosphatidylethanolamine-polyethylene glycol, the distearoylphosphatidylethanolamine-polyethylene glycol-amino and the TPGS are prepared by a thin film dispersion method to obtain TPGS-containing liposomes;

[0020] 2) Using glutaraldehyde as a linker, the ADH-1 is linked to the amino group of the TPGS-containing liposome to obtain the targeted liposome.

[0021] In step 1) of the above method, the thin film dispersion method specifically comprises the following steps: dissolving the lecithin, the β-sitosterol, the distearoylphosphatidylethanolamine-polyethylene glycol, the distearoylphosphatidylethanolamine-polyethylene glycol-amino and the TPGS in an appropriate amount of organic solvent, performing rotary evaporation under reduced pressure to remove the organic reagent, then adding an appropriate amount of hydration medium, ultrasonically hydrating, and membrane filtering to obtain liposomes containing TPGS.

[0022] Specifically, the organic solvent may be methanol; and the hydration medium may be 250 mM ammonium sulfate solution.

[0023] The membrane filtration refers to passing through 0.4 μm and 0.2 μm polycarbonate membranes three times in sequence.

[0024] The specific method of step 2) of the above method is as follows: the ADH-1 and the TPGS-containing liposomes are mixed evenly, and glutaraldehyde is slowly dripped to make the final concentration of glutaraldehyde reach 12-18mM (specifically 15mM); ADH-1 is connected to the amino end of DSPE-PEG2000-NH2 on the surface of the TPGS-containing liposomes using glutaraldehyde as a linker, and the mixture is incubated at room temperature for 5 minutes and then placed in a dialysis bag, and dialyzed in a PBS buffer solution at pH 7.4 to remove unconnected ADH-1 and glutaraldehyde to obtain targeted liposomes.

[0025] Another object of the present invention is to provide a targeted drug-loaded liposome.

[0026] The targeted drug-loaded liposome provided by the present invention is obtained by encapsulating the drug in the above-mentioned targeted liposome.

[0027] The drug is selected from at least one of the following: isoimperatorin, β-sitosterol, tartaric acid, ragweed, quercetin, kaempferol and luteolin, alismatol, alismat diterpenoid glycosides, alismatol C monoacetate, alismatol A, alismatol B, 11-deoxy alismatol, alismat diterpenoid glycosides; preferably ragweed.

[0028] The drug-to-lipid ratio of the drug-loaded liposome is 1:4-6, preferably 1:5.

[0029] The drug-lipid ratio is defined as: the ratio of the mass of the drug to the sum of the masses of the phosphatidylcholine and the β-sitosterol in the targeted liposome.

[0030] The present invention also provides a method for preparing the above-mentioned targeted drug-loaded liposome, comprising the following steps:

[0031] a) Preparation of drug-loaded liposomes containing TPGS:

[0032] The lecithin, the cholesterol, the distearoylphosphatidylethanolamine-polyethylene glycol, the distearoylphosphatidylethanolamine-polyethylene glycol-amino, the TPGS and the drug are prepared by a thin film dispersion method to obtain a drug-loaded liposome containing TPGS;

[0033] b) Using glutaraldehyde as a linker, the ADH-1 is linked to the amino group of the drug-loaded liposome containing TPGS, thereby obtaining the targeted drug-loaded liposome.

[0034] According to one embodiment of the present invention, in the targeted drug-loaded liposomes, the mass proportions of each raw material are: 37.5 parts of lecithin, 12.5 parts of β-sitosterol, 1-2.5 parts of distearoylphosphatidylethanolamine-polyethylene glycol, 1-2.5 parts of distearoylphosphatidylethanolamine-polyethylene glycol-amino, 3-4 parts of TPGS, and 8-12 parts of tricholoma.

[0035] Another object of the present invention is to provide the application of the drug-loaded liposome.

[0036] The application of the drug-loaded liposome provided by the present invention is any one of the following applications 1)-7):

[0037] 1) Preparation of drugs for preventing and / or treating tumors;

[0038] 2) Preparation of drugs for preventing and / or treating tumor metastasis;

[0039] 3) Preparation of products for inhibiting the proliferation of eukaryotic tumor cells;

[0040] 4) Preparation of products that promote apoptosis of eukaryotic tumor cells;

[0041] 5) Preparation of products for inhibiting the migration of eukaryotic tumor cells;

[0042] 6) Preparation of products for inhibiting epithelial-mesenchymal transition in non-small cell lung cancer;

[0043] 7) Prepare products that enhance the drug uptake ability of eukaryotic tumor cells.

[0044] The tumor is cancer; the cancer may specifically be lung cancer, prostate cancer or glioma; the lung cancer may further be non-small cell lung cancer, and further be lung adenocarcinoma.

[0045] The eukaryotic organism is a human or a mammal; the tumor cell is a cancer cell; the cancer cell includes lung cancer cells (specifically A549 lung adenocarcinoma cells), prostate cancer cells (specifically PC-3 prostate cancer cells), and glioma cells (C6 glioma cells).

[0046] The present invention uses a systems pharmacology approach and, with the help of data analysis and processing tools such as the Traditional Chinese Medicine Systems Pharmacology Analysis Platform (TCMSP) database, conducts an in-depth study on the anti-tumor effects and drugability of the active ingredients in Saussurea involucrata, providing new ideas and models for the discovery and screening of active ingredients in Saussurea involucrata, a special botanical medicine in Xinjiang, and a new means for the in-depth development of Saussurea involucrata.

[0047] The present invention encapsulates the active ingredient of Saussurea involucrata, which has strong anti-tumor activity, into liposomes, and coats a layer of TPGS on the surface of the prepared liposomes to enhance the toxicity of the nanocarrier to tumor cells and improve cell uptake. The most important thing is to increase the encapsulation rate and drug loading of the Saussurea involucrata with the help of TPGS to solve the problems of low encapsulation rate and drug loading of the existing dosage form, while inhibiting the expression of P-glycoprotein, reducing the efflux of intracellular drugs, and increasing the drug concentration in tumor cells. Then, the ADH-1 polypeptide that can specifically target the invasion and metastasis sites is modified on the surface of the liposome to construct a multifunctional nano-targeted carrier. It can not only enhance the therapeutic effect of the active ingredient of Saussurea involucrata on epithelial-mesenchymal transition of non-small cell lung cancer, but also reduce metastasis and side effects, and is expected to become a safe and feasible solution for treating lung cancer metastasis.

[0048] The present invention uses a systemic pharmacology method to screen the active ingredients in Saussurea involucrata, and analyzes and verifies its anti-cancer mechanism. Then, the ragweed genus with strong anti-tumor activity is selected as the target drug, and the functionalized liposomes of Saussurea involucrata are constructed. The polypeptide ADH-1 with the effect of treating tumor cell migration and invasion is modified to the surface of the liposome, which can enhance the therapeutic effect of the active ingredients of Saussurea involucrata on epithelial-mesenchymal transition of non-small cell lung cancer, and has the effect of targeting tumor cells; TPGS is modified to the surface of the liposome to enhance the toxicity of the nanocarrier to tumor cells and improve cell uptake. The most important thing is to increase the encapsulation rate and drug loading of ragweed genus with the help of TPGS to solve the problem of low encapsulation rate and drug loading of the existing dosage form. The active compound of Saussurea involucrata obtained by screening is loaded into the liposome to obtain the functionalized targeted nanocarrier of Saussurea involucrata, which can enable more drugs to reach the lesion site, greatly improve the chemotherapy effect, enhance the inhibitory effect of epithelial-mesenchymal transition, reduce metastasis and side effects, and is expected to provide a safe and feasible treatment plan for the treatment of lung cancer metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 Particle size legends for each group of liposomes constructed: A: blank liposomes; B: ragweed liposomes; C: TPGS-ragweed liposomes; D: ADH-1 ragweed liposomes; E: Saussurea involucrata functionalized targeted liposomes.

[0050] Figure 2 This is the cumulative release curve of tricholoma tenuifolia in the liposomes in Example 2.

[0051] Figure 3 It is a transmission electron microscope photograph of the drug-loaded liposome (HIS-liposome) of the present invention.

[0052] Figure 4 The morphological changes of A549 cells induced by TGF-β1 (×200); Note: A: control group; B: TGF-β1 induced group.

[0053] Figure 5 The MTT method was used to determine the antiproliferative effects of various preparations of ragweed on A549 lung adenocarcinoma cells.

[0054] Figure 6 The MTT method was used to determine the anti-proliferative effects of various preparations of ragweed on A549 lung adenocarcinoma cells after modeling.

[0055] Figure 7 Fluorescence images of drugs and dosage forms after incubation with A549 cells (10X)

[0056] Note: A: blank control; B: β-sitosterol liposomes; C: free ragweed; D: ragweed liposomes; E: TPGS-ragweed liposomes; F: ADH-1 ragweed liposomes; G: ADH-1-TPGS ragweed liposomes.

[0057] Figure 8 Fluorescence images of A549 cells after incubation with drugs and each dosage form group and modeling (10X)

[0058] Note: A: blank control; B: modeling group; C: β-sitosterol liposomes; D: free ragweed; E: ragweed liposomes; F: TPGS-ragweed liposomes; G: ADH-1 ragweed liposomes; H: ADH-1-TPGS ragweed liposomes.

[0059] Fig. 9 The uptake of different groups of drugs by A549 cells

[0060] A: Summary of fluorescence intensity of uptake by each group; B: Analysis of fluorescence intensity of uptake of nanocarriers by A549 cells in each group.

[0061] Fig.10 The uptake of different groups of drugs by A549 cells after modeling

[0062] A: Summary of fluorescence intensity of uptake by each group; B: Analysis of fluorescence intensity of uptake of nanocarriers by A549 cells after modeling.

[0063] Fig.11 Effect of Saussurea involucrata functionalized nanocarriers on apoptosis of A549 cells

[0064] A: blank control; B: β-sitosterol liposomes; C: free ragweed; D: ragweed liposomes; E: TPGS-ragweed liposomes; F: ADH-1 ragweed liposomes; G: ADH-1-TPGS ragweed liposomes; H: apoptosis level of A549 lung cancer cells.

[0065] Fig.12 The Tianshan Saussurea functionalized nanocarriers inhibited the healing ability of A549 cells (×100).

[0066] Fig.13 This is an invasion experiment of lung adenocarcinoma A549 cells (×200); Note: AH: A549 cells were treated with different drugs for 24 hours; A is the control group; TGF-β1 was added to BE; the concentration of trichometurin in CE was 40μM; CE: β-L, FreeH, HL, THL, AHL and ATHL.

[0067] Fig.14 This is an invasion experiment of lung adenocarcinoma A549 cells (×200); Note: AH: A549 cells were treated with different drugs for 48 hours; A is the control group; TGF-β1 was added to BE; the concentration of trichometurin in CE was 40μM; CE: β-L, FreeH, HL, THL, AHL and ATHL.

[0068] Fig.15 Analysis of preparations in each group in Transwell in vitro invasion experiment

[0069] Note: A: 24h; B: 48h.

[0070] Fig.16 This is the regulation of tricholoma arachnoides on E-cadherin, N-cadherin and Vimentin proteins in A549 cells. DETAILED DESCRIPTION

[0071] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0072] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0073] The reagents and instruments used in the following examples are as follows:

[0074] 1. Experimental reagents and cells

[0075] Egg yolk phosphatidylcholine (EPC) was purchased from Germany Lipoid Company, ShangHai local agent, China; β-sitosterol was purchased from MedChemexpress Biotechnology Company, USA; polyethylene glycol-distearoylphosphatidylethanolamine (DSPE-PEG2000) and DSPE-PEG2000-NH2 were purchased from Avanti Polar Lipids Company, USA; ADH-1 was purchased from Shanghai Jier Biochemical Co., Ltd. (Batch No. 500712); dextran gel (shephedex G-50) and trinitrobenzenesulfonic acid (TNBS) were purchased from Sigma; ammonium sulfate ((NH4)2SO4), analytical grade, was purchased from Tianjin Fuchen Chemical Reagent Factory; 0.25% trypsin was purchased from Gibico; sulforhodamine B protein (SRB) was purchased from Sigma, USA; A549 lung adenocarcinoma cells (Wuhan Pronosai Life Science Technology Co., Ltd.); DMEM-F12 basal medium, RPMI-1640 culture medium and double antibody (Gibco, USA); 5× protein loading buffer (Beijing Kangwei Century Biotechnology Co., Ltd., batch number CW0028); fetal bovine serum (BI, Israel, batch number 1850107); RIPA tissue cell lysis buffer (Beijing Solebow Technology Co., Ltd., batch number R0010); rough hair ragweed (purity> 98%, Shanghai Tongtian Biotechnology Co., Ltd., batch number 19090601); horseradish enzyme-labeled goat anti-rabbit IgG and horseradish enzyme-labeled goat anti-mouse IgG (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., batch numbers 131224 and 139931 respectively); supersignal TM west femto maximum sensitivity substrate (ThermoFisher, USA); Anti-βactin (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.); phenylmethylsulfonyl chloride (PMSF), sodium dodecyl sulfate (SDS), tris (Tris) and protein phosphatase inhibitor cocktail (Beijing Solebao Technology Co., Ltd.); ammonium persulfate, glycine and Tween-20 (Beijing Bio-Toda Technology Co., Ltd.); sodium chloride (Shanghai Yongsheng Fine Chemical Co., Ltd.); methanol (analytical grade); Matrigel TM basement membrane matrix gel (BD Company, USA, model 356234); transforming growth factor β1 (TGF-β1) (PeproTech Company, USA, batch number 0218209-2); 6-well plate, 24-well plate (Corning Company, USA); E-cadherin, Vimentin and N-cadherin antibodies (Abcam Company, UK); 0.1% crystal violet aqueous solution and 4% paraformaldehyde (Beijing Solebow Technology Co., Ltd.); transwell polycarbonate membrane insert (Corning, USA, model: 3422, 8.0 μm).

[0076] 2. Experimental instruments

[0077] Polycarbonate filters (pore size of 400 and 200 nm) were purchased from Millipore (Bedford, MA, USA); Shimadzu LC-15C high performance liquid chromatograph (Shimadzu Corporation, Japan, UV detector); UV-2401PC UV-visible spectrophotometer (Shimadzu Corporation, Japan); Malvern particle size analyzer (Malvern Instruments, UK); Sartorius BP211D electronic balance (Sartorius Group, Germany); ultrasonic cleaner (Tianpeng Electronic New Technology Beijing Co., Ltd.); EYELA-1000S rotary evaporator (EYELA Tokyo Rikagaki Co., Ltd., Japan); JY92 cell ultrasonic disruptor (Ningbo Xinzhi Biotechnology Co., Ltd.); constant temperature oscillator (Jintan Medical Instrument Factory, Jiangsu Province); dialysis bag (molecular weight cutoff 8000-12000); liposome extruder (Sartorius Group, Germany); flow cytometer (BD Company, USA); CO2 constant temperature incubator (Thermo Technology Co., Ltd., USA); enzyme immunoassay instrument (Shanghai Gene Technology Co., Ltd.); inverted microscope (O-1000, Japan); lympus company, model TH4-200); CO2 constant temperature incubator (Thermo Fisher Scientific Inc., USA); electronic balance (Sartorius Group, Germany, model SartoriusBP211D); refrigerated centrifuge (Eppendorf, Germany, model TGL-16G); dual vertical electrophoresis apparatus (Beijing Liuyi Biotechnology Co., Ltd., model DYCZ-25D); membrane transfer apparatus (Hoefer, USA, model TE77PWR); UVP gel imaging system (UVP, USA, model EC3TM 510); Quawell ultra-micro UV / visible spectrophotometer (Quawell, USA, model Q5000); high pressure steam sterilizer (Hirayama, Japan, model HVE-50).

[0078] Example 1: Preparation technology and formulation research of Saussurea involucrata functionalized targeted liposomes

[0079] 1. Preparation of blank liposomes (β-sitosterol liposomes)

[0080] Take the prescribed amount of lecithin 37.5-40 mg (specifically 37.6 mg), β-sitosterol 10-12.5 mg (specifically 12.38 mg), DSPE-PEG 20001-2 mg (specifically 1.92 mg), slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film. Add 5 ml of 250 mM ammonium sulfate for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min), ultrasonically reduce the particle size on a cell disruptor, and pass through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times each after water bath for particle size adjustment to obtain blank liposomes.

[0081] 2. Preparation of Tianshan Saussurea Active Compound Liposomes (HIS Liposomes)

[0082] Weigh the prescribed amount of membrane materials (lecithin, β-sitosterol, DSPE-PEG 2000 The dosage is the same as that of blank liposomes) and the raw material of the active compound of Saussurea involucrata (8-12 mg of tricholoma tricholoma, specifically 9.97 mg) are dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, and slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film, and 5 ml of 250 mM ammonium sulfate is added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min). After complete hydration, the mixture is transferred to a 5 mL serum bottle, and the particles are ultrasonically granulated with a cell disruptor, and the particles are preheated in a constant temperature water bath at 60°C for 3-5 min, and respectively passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times, and free tricholoma tricholoma active compound liposomes are obtained by using Sephadex G-50 column chromatography.

[0083] 3. Preparation of TPGS-targeted liposomes (TPGS-HIS liposomes)

[0084] Weigh the prescribed amount of membrane materials (lecithin, β-sitosterol, DSPE-PEG 2000 The dosage is the same as that of blank liposomes), the raw material of the active compound of Saussurea involucrata (8-12 mg of tricholoma tricholoma, specifically 9.94 mg) and TPGS (3-4 mg, specifically 3.30 mg) are dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, and slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film, and 5 ml of 250 mM ammonium sulfate is added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min). After complete hydration, the mixture is transferred to a 5 mL serum bottle, and the particles are ultrasonically granulated by a cell disruptor, and the particles are preheated in a constant temperature water bath at 60°C for 3-5 min, and respectively passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times, and free tricholoma tricholoma active compound is removed by Sephadex G-50 column chromatography to obtain TPGS targeted liposomes.

[0085] 4. Preparation of ADH-1 targeted liposomes (ADH-1-HIS liposomes)

[0086] Weigh the prescribed amount of membrane materials (lecithin, β-sitosterol, DSPE-PEG 2000 The dosage of liposomes was the same as that of blank liposomes; distearoylphosphatidylethanolamine-polyethylene glycol-amino (DSPE-PEG 2000 -NH2) 1-2.5 mg, specifically 2.26 mg) and the raw material of the active compound of Saussurea tianshanica (8-12 mg of tricholoma tricholoma, specifically 9.86 mg) were dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, and slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film, and 5 ml of 250 mM ammonium sulfate was added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min). After complete hydration, the mixture was transferred to a 5 mL serum bottle, and the particles were ultrasonically granulated by a cell disruptor, and the mixture was preheated in a constant temperature water bath at 60°C for 3-5 min, and passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times respectively, and free tricholoma tricholoma active compound liposomes were removed by Sephadex G-50 column chromatography to obtain Saussurea tianshanica active compound liposomes.

[0087] ADH-1 was added to the constructed Saussurea involucrata active compound liposomes and mixed evenly (liposome 20 ml, ADH-1 0.5-1 mg (specific amount 0.63 mg)), glutaraldehyde was slowly dripped to make the final concentration of glutaraldehyde reach 15 mM, and glutaraldehyde was used as a linker to connect ADH-1 to the DSPE-PEG on the surface of Saussurea involucrata active compound liposomes. 2000 -NH2, incubated at room temperature for 5 minutes, then placed in a dialysis bag (molecular weight 8000-14000), dialyzed in PBS (pH 7.4) to remove unconnected ADH-1 and glutaraldehyde, and obtained ADH-1 targeted liposomes.

[0088] 5. Construction of Tianshan Saussurea functionalized liposomes (ADH-1-TPGS-β-HIS liposomes)

[0089] Weigh the prescribed amount of membrane material, Tianshan Saussurea active compound raw material (coarse hair ragweed) and TPGS (lecithin 37.5-40 mg, specifically 36.47 mg; β-sitosterol 10-12.5 mg, specifically 12.48 mg; distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG2000) 1-2.5 mg, specifically 2.26 mg; distearoylphosphatidylethanolamine-polyethylene glycol-amino (DSPE-PEG 2000-NH2) 1-2.5 mg, specifically 2.24 mg; 8-12 mg, specifically 9.93 mg; 3-4 mg, specifically 3.29 mg of TPGS) were dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film, 5 ml of 250 mM ammonium sulfate was added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min), and after complete hydration, the mixture was transferred to a 5 mL serum bottle, and the particles were ultrasonically granulated with a cell disruptor, and the mixture was preheated in a constant temperature water bath at 60°C for 3-5 min, and passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times respectively, and the free 1,2-dihydrotestosterone, an active compound of Saussurea involucrata, was removed by Sephadex G-50 column chromatography to obtain TPGS targeted liposomes.

[0090] ADH-1 was added to the constructed TPGS targeted liposomes and mixed evenly (20 ml of TPGS targeted liposomes, 0.5-1 mg of ADH-1 (specific dosage was 0.64 mg)), and glutaraldehyde was slowly dripped to make the final concentration of glutaraldehyde reach 15 mM. Glutaraldehyde was used as a linker to connect ADH-1 to the DSPE-PEG on the surface of the Tianshan Saussurea nanosystem. 2000 -NH2, incubated at room temperature for 5 minutes, placed in a dialysis bag (molecular weight 8000-14000), dialyzed in PBS (pH 7.4) to remove unconnected ADH-1 and glutaraldehyde, and obtained Tianshan Saussurea functionalized liposomes.

[0091] 6. Determination of encapsulation efficiency

[0092] The prepared ragweed liposomes were separated by Sephadex G-50 from the free ragweed that was not encapsulated in the liposomes, and eluted with PBS phosphate buffer. The conditions of the Sephadex G-50 column used in the separation experiment were as follows: sample volume: 2.0 mL; column height: 2 cm (inner diameter) × 15 cm (height); eluent: PBS phosphate buffer. Prepare an appropriate amount of ragweed liposomes before column, and use 9 volumes of methanol to break the emulsion and use it to determine the content of total ragweed; prepare the liposome solution after column, break the emulsion with methanol, and determine the content of ragweed in the ragweed liposomes. Calculate the drug encapsulation efficiency according to formula (1), and the drug loading amount according to formula (2)

[0093] Encapsulation rate % = Wa / Wb × 100% (Formula 1) Drug loading % = WA / WB × 100% (Formula 2)

[0094] Where Wa represents the amount of drug entrapped in the liposomes after passing through the column; Wb is the drug content entrapped in the liposomes before passing through the column; WA is the drug content in the liposomes; and WB is the total amount of membrane material and drug input during the liposome preparation process.

[0095] 7. Effect of phospholipid β-sitosterol ratio on encapsulation efficiency

[0096] The amount of ragweed was fixed at 2.5-5 mg (specifically: 3.33 mg), and the effects of the ratio of phospholipid to β-sitosterol on the encapsulation efficiency of ragweed were investigated at 2:1 (26-40 mg: 13-20 mg; specifically: 34.63 mg: 16.85 mg), 3:1 (37.5-40 mg: 10-12.5 mg; specifically: 37.22 mg: 12.42 mg), 4:1 (24-36 mg: 8-12 mg; specifically: 39.73 mg: 10.05 mg), 5:1 (24-50 mg: 6-10 mg; specifically: 41.30 mg: 8.52 mg), and 6:1 (30-48 mg: 5-8 mg; specifically: 42.45 mg: 7.17 mg), and the stability of liposomes at different ratios of phospholipid to β-sitosterol were observed. The raw materials used in the preparation of liposomes here are only: ragweed, phospholipids and β-sitosterol.

[0097] In the experiment, the encapsulation efficiency was investigated by using the dextran gel G-50 column chromatography method. The results are shown in Table 1. When the ratio of phospholipid to β-sitosterol was 3:1, the encapsulation efficiency was the highest, which was 44.74±0.01%. Therefore, the optimal phospholipid β-sitosterol mass was selected to be 3:1.

[0098] Table 1 Screening of the optimal ratio of phospholipids to β-sitosterol (n=3)

[0099]

[0100]

[0101] Note: ****.P<0.0001, compared with 3:1 group,

[0102] 8. Effect of drug-lipid ratio of tricholoma serrata on encapsulation efficiency

[0103] According to the process screening of 7, the ratio of fixed phospholipids to β-sitosterol was 3:1 (37.5 mg:12.5 mg). The mass ratio of ragweed to membrane material (phospholipid + β-sitosterol) was set to 1:5 (8-12 mg: 40-60 mg; specifically: 9.9 mg: 49.48 mg), 1:10 (4-6 mg: 40-60 mg; specifically: 4.92 mg: 49.71 mg), 1:15 (2.5-4 mg: 40-60 mg; specifically: 3.27 mg: 49.74 mg), 1:20 (2-3 mg: 40-60 mg; specifically: 2.45 mg: 49.78 mg), 1:30 (1-2 mg: 40-60 mg; specifically: 1.60 mg: 49.64 mg), and the encapsulation efficiency and drug loading of ragweed in each experimental group were investigated, and the stability of the liposomes was observed. The raw materials used in the preparation of the liposomes here were only: ragweed, phospholipids and β-sitosterol.

[0104] The results are shown in Table 2. It can be seen from the table that the 1:20 group had the highest encapsulation rate of 44.74±0.01%, and the 1:5 group had the highest drug loading of 6.61±0.02%. Therefore, considering the encapsulation rate and drug loading, the 1:5 group was finally determined to be the best drug-lipid ratio, because the drug loading at this time was significantly higher than that of the other groups, and the encapsulation rate was less different from that of the 1:20 group.

[0105] Table 2 Screening of the optimal ratio of ragweed to lipid (n=3)

[0106]

[0107] Note: ****.P<0.0001, compared with 1:5 group,

[0108] 9. Preparation of different liposomes and determination of their encapsulation efficiency

[0109] According to the experimental method of 2-5, HIS liposomes (specifically: HIS: 7.47 mg, lecithin: 37.67 mg, β-sitosterol: 12.50 mg), TPGS-HIS liposomes (specifically: HIS: 9.97 mg, lecithin: 29.20 mg, β-sitosterol: 9.74 mg, TPGS: 3.30 mg), ADH-1-HIS liposomes (specifically: HIS: 9.83 mg, lecithin: 37.66 mg, β-sitosterol: 12.52 mg, DSPE-PEG 2000 : 2.25mg, DSPE-PEG 2000-NH2: 2.24 mg) and ADH-1-TPGS-HIS liposomes (specifically: HIS: 9.94 mg, phosphatidylcholine: 36.44 mg, β-sitosterol: 12.38 mg, TPGS: 3.30 mg, DSPE-PEG 2000 : 2.25mg, DSPE-PEG 2000 -NH2: 2.23mg), and the encapsulation efficiency was determined according to 6. The results are shown in Table 3. It can be seen from the table that TPGS can significantly improve the encapsulation efficiency of trichometurin.

[0110] Table 3 Drug loading and encapsulation efficiency of each dosage form group prepared (n=3)

[0111]

[0112] Note: **.P<0.01, ***.P<0.001, ****.P<0.0001. Compared with TPGS-ADH-1-HIS-L group.

[0113] Example 2: Study on the physicochemical properties of Saussurea involucrata functionalized targeted liposomes

[0114] 1. Particle size analysis of Saussurea involucrata functionalized targeted liposomes

[0115] The particle size analysis of liposomes is one of the important indicators for characterizing the functionalized targeted liposomes of Saussurea involucrata. In this experiment, a light scattering particle size analyzer was used to detect the average particle size, polydispersity coefficient and Zeta potential of the sample group. All samples were diluted ten times for detection. The particle size, PDI and Zeta potential results of different sample groups are shown in Table 4. It can be seen from the table that the particle size of the target drug delivery system is 110.20±0.37nm, the PDI is 0.096±0.005, and the Zeta potential is -15.37±0.12, which confirms that the particle size of the target liposomes prepared in this experiment is uniform, the dispersion is good, and the stability is strong. Compared with the blank liposome group, the particle size of other liposome groups has increased, which may be related to the polarity and steric hindrance of the drug, but it can be seen from the PDI and Zeta potential that all liposome groups have good dispersion and stability. In addition, Figure 1 also more intuitively proves the uniformity and particle size concentration of each liposome group, indicating that the quality is good and can be used for subsequent experimental investigations.

[0116] Table 4 Particle size and Zeta potential of different nanocarriers (n=3)

[0117]

[0118] 2. In vitro drug release study of Saussurea involucrata functionalized targeted liposomes

[0119] Accurately measure 1 mL of blank liposomes, ragweed liposomes, TPGS-ragweed liposomes, ADH-1 ragweed liposomes and Saussurea involucrata functionalized targeted liposome suspensions, and add them to the treated dialysis bag. Place the dialysis bag in the release medium, add 0.05% Tween 80, and at the same time meet the sink condition and oscillate at a constant speed in a constant temperature oscillator under 37±0.5℃ water bath conditions. Take out 1 mL of release medium at the set time points, and add the same volume of release medium at the same time. The taken out solution is analyzed and determined by HPLC. The release percentage is calculated according to the formula: F(%) = (Ct / Ctotal) × 100% (Ct is the actual concentration at each time point and the solution concentration calculated according to the labeled amount). The results are shown in Tables 5 and Figure 2 .

[0120] From Table 5 and Figure 2 It can be seen that the free drug showed a burst release phenomenon, and the release rate was significantly faster than that of the other four drug-loaded groups, indicating that liposomes can enhance the sustained-release effect of drugs.

[0121] Table 5 Cumulative release rate of tricholoma serrata in nanocarriers (n=3)

[0122]

[0123]

[0124] ③ Transmission electron microscopy observation of liposome morphology

[0125] After the liposome suspension is dispersed with deionized water, it is passed through a membrane and dripped onto a copper mesh. When the copper mesh is covered with the liposomes to be tested, it is taken out after about 1 minute, and the filter paper is used to absorb the surface. The copper mesh is placed face down in 2% phosphotungstic acid, and taken out after 1-2 minutes. The unbound dye is washed with clean water for three times, and then dried under a lamp. The morphology of the liposomes is observed by transmission electron microscopy. Figure 3 It can be seen that the particle size of the liposome is about 100 nm, the particle size is relatively uniform, and the prepared liposome has a relatively round shape as a whole.

[0126] Example 3: In vitro pharmacodynamic evaluation of Saussurea involucrata functionalized targeted liposomes

[0127] 1. Establishing the EMT model

[0128] A549 cells in the logarithmic growth phase were taken and 5×10 5 / well were inoculated in a six-well plate and incubated overnight in an incubator to allow them to grow on the wall. After 12 hours of serum-free culture, TGF-β1 was added to the modeling group to a final concentration of 10 ng / mL, and the control group was added with an equal amount of serum-free culture medium and cultured in an incubator, and the cell morphology was observed after 48 hours.

[0129] An inverted phase contrast microscope was used to observe lung adenocarcinoma A549 cells before and after modeling. The results were as follows: before TGF-β1 induction, lung adenocarcinoma A549 cells were cobblestone-like and polygonal-like, and arranged relatively tightly; after TGF-β1 induction, lung adenocarcinoma A549 cells changed from cobblestone-like before induction to long spindle-like and spindle-like, the connection between cells became looser, and the gaps between cells increased. After induction, the cells changed from the original epithelial phenotype to the mesenchymal phenotype, showing the characteristics of mesenchymal cells. See Figure 4 .

[0130] 2. MTT assay to detect the inhibitory effect of liposomes on the proliferation of A549 lung cancer cells in vitro and after modeling

[0131] A549 lung adenocarcinoma cells and A549 cells after modeling were seeded in a 96-well cell culture plate at a density of 5000 cells per well and cultured in an incubator. Prepare a series of blank liposome concentrations (specifically: take 400 μL of blank liposomes and add 100 μL of serum-free medium to obtain 80 μM, the mother solution is 100 μM, and the other groups are diluted from the 80 μM group), free HIS group (specifically: take 12 μL of ragweed and add 583 μL of serum-free medium to obtain a 100 μM solution, and the other groups are diluted from the 100 μM group), ragweed liposomes (specifically: take 242 μL of ragweed liposomes and add 158 μL of serum-free medium to obtain a 40 μM solution, add 32 μM to each well of the 100 μM group, 25 μM to each well of the 80 μM group, and 19 μM to each well of the 60 μM group, and the other groups are diluted from the 100 μM group), TPGS-HIS liposomes (specifically: 205 μL of TPGS-HIS liposomes were added to 195 μL of serum-free medium to obtain a 20 μM solution, 66 μM was added to each well of the 100 μM group, 48 μM was added to each well of the 80 μM group, 33 μM was added to each well of the 60 μM group, 20.6 μM was added to each well of the 40 μM group, and the remaining groups were diluted from the 20 μM group), ADH-1-HIS liposomes (specifically: 183 μL of ADH-1-HIS liposomes were added to 217 μL of serum-free medium to obtain a 20 μM solution, 100 μM 56 μM was added to each well of the 100 μM group, 41 μM was added to each well of the 80 μM group, 29 μM was added to each well of the 60 μM group, 18 μM was added to each well of the 40 μM group, and the rest of the groups were diluted from the 20 μM group), ADH-1-TPGS-HIS liposomes (specifically, 236 μL of ADH-1-TPGS-HIS liposomes were added to 164 μL of serum-free culture medium to obtain a 40 μM solution, 32 μM was added to each well of the 100 μM group, 24 μM was added to each well of the 80 μM group, 17 μM was added to each well of the 60 μM group, and the rest of the groups were diluted from the 40 μM group), so that the final concentration gradient of ragweed in each group was: 0, 1.25, 2.5, 5, 10, 20, 40, 60, 80, 100 μM, and a solvent control group was set, and three replicate wells were set for each concentration. After the cells adhered to the wall, 20 μL of the liposome suspension was added to each well of the plate. After culturing for 24 h, the culture plate was treated according to the MTT method. The absorbance OD value of each well at 540 nm was measured on a microplate reader to calculate the cell growth inhibition rate.

[0132] MTT method was used to determine the antiproliferative effects of various preparations of ragweed on A549 lung adenocarcinoma cells. Figure 5 As shown. Figure 5It can be seen that compared with other preparation groups, the free ragweed group has a weaker inhibitory effect on the proliferation of A549 cells; and the prepared ADH-1-TPGS-HIS liposomes have a better anti-proliferative effect on A549 than other drug-loaded liposome groups. It can also be clearly seen from the figure that the blank liposomes have little effect on the proliferation inhibition of lung adenocarcinoma A549 cells.

[0133] MTT method was used to determine the antiproliferative effects of various preparations of ragweed on A549 lung adenocarcinoma cells after modeling. Figure 6 As shown. Figure 6 It can be seen that among the various ragweed preparation groups, the ability to inhibit the proliferation of A549 cells after modeling is from strong to weak: ADH-1-TPGS-HIS liposomes > ADH-1-ragweed liposomes > TPGS-ragweed liposomes > ragweed liposomes > free ragweed.

[0134] 3. DAPI labeling of live cells

[0135] The antiproliferative effect of Saussurea involucrata functionalized nanocarriers on A549 cells and A549 cells after modeling was evaluated by fluorescence microscopy. A549 cells and A549 cells after modeling were firstly cultured at 3×10 5 The cells were inoculated at a density of 100 cells / mL in a 6-well cell culture plate and cultured in an incubator. Different experimental groups were prepared, namely, a blank control group, a ragweed liposome group, a TPGS-ragweed liposome group, an ADH-1-ragweed liposome group, and a Tianshan Saussurea functionalized nanocarrier group (i.e., an ADH-1-TPGS ragweed liposome). The solutions of each experimental group prepared above were added to the culture plate. After incubation for 48 hours, the living cells were labeled with DAPI to examine the survival status of the tumor cells after administration.

[0136] The results are as follows Figure 7 and Figure 8 As shown, living cells were labeled with DAPI, and the blue color indicated that the cells were alive. The anti-tumor effects of different experimental groups were visually compared by observing the fluorescence effect.

[0137] 4. Ingestion experiment

[0138] Coumarin-6 is a fat-soluble dye with strong fluorescence properties. Therefore, it is widely used to study the distribution and transport of drug delivery systems in vivo and in vitro uptake experiments. In this experiment, coumarin-6 was encapsulated in each group of liposomes, and the purpose was to measure the fluorescence intensity by flow cytometry to study the in vitro uptake of A549 cells.

[0139] (1) Preparation of coumarin 6-β-sitosterol liposomes (coumarin 6-blank liposomes)

[0140] Take the prescribed amount of lecithin 37.5-40 mg (specifically 37.74 mg), β-sitosterol 10-12.5 mg (specifically 12.39 mg), DSPE-PEG 2000 1-2.5mg (specifically 2.23mg) and coumarin 6 2-3mg (specifically 2.68mg) were slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film. 5ml of 250mM ammonium sulfate was added for ultrasonic hydration (ultrasonic conditions: power 60W, time 10min), and ultrasonicated on a cell disruptor to reduce the particle size. After a water bath, the particles were passed through 0.4μm and 0.2μm polycarbonate membranes for 3 times each for particle size adjustment to obtain coumarin 6-β-sitosterol liposomes.

[0141] (2) Preparation of coumarin 6-coumarin-liposomes

[0142] Weigh the prescribed amount of lecithin 37.5-40 mg (specifically 39.44 mg), β-sitosterol 10-12.5 mg (specifically 12.42 mg), DSPE-PEG 2000 1-2.5 mg (specifically 2.25 mg), the raw material of the active compound of Saussurea involucrata (8-12 mg of tricholoma tricholoma, specifically 9.01 mg) and coumarin 6 2-3 mg (specifically 2.49 mg) were dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, slowly vacuumed and rotated at 39°C on a rotary evaporator to form a film, 5 ml of 250 mM ammonium sulfate was added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min), and after complete hydration, the mixture was transferred to a 5 mL serum bottle, ultrasonically granulated with a cell disruptor, and preheated in a constant temperature water bath at 60°C for 3-5 min, respectively, and passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times each, and free tricholoma tricholoma active compound was removed by Sephadex G-50 column chromatography to obtain coumarin 6-tricholoma tricholoma-liposomes.

[0143] (3) Preparation of coumarin 6-TPGS-coarse ragweed liposomes

[0144] Weigh the prescribed amount of lecithin 37.5-40 mg (specifically 39.66 mg), β-sitosterol 10-12.5 mg (specifically 12.47 mg), DSPE-PEG 20001-2.5 mg (specifically 2.46 mg), the raw material of the active compound of Saussurea involucrata (8-12 mg of tricholoma tricholoma, specifically 9.49 mg), TPGS (3-4 mg, specifically 3.89 mg) and coumarin 6 2-3 mg (specifically 2.69 mg) were dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film, 5 ml of 250 mM ammonium sulfate was added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min), and after complete hydration, the mixture was transferred to a 5 mL serum bottle, and the particles were ultrasonically granulated by a cell disruptor, and the mixture was preheated in a constant temperature water bath at 60°C for 3-5 min, and respectively passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times each, and the free tricholoma tricholoma active compound was removed by Sephadex G-50 column chromatography to obtain TPGS targeted liposomes.

[0145] (4) Preparation of coumarin 6-ADH-1-coarse ragweed-liposomes

[0146] Weigh the prescribed amount of lecithin 37.5-40 mg (specifically 39.73 mg), β-sitosterol 10-12.5 mg (specifically 12.38 mg), DSPE-PEG 2000 1-2.5 mg (specifically 2.37 mg), the raw material of the active compound of Saussurea involucrata (8-12 mg of tricholoma tricholoma, specifically 9.60 mg) and 2-3 mg of coumarin 6 (specifically 2.51 mg) were dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, slowly vacuumed and rotated at 39°C on a rotary evaporator to form a film, 5 ml of 250 mM ammonium sulfate was added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min), and after complete hydration, the mixture was transferred to a 5 mL serum bottle, and the particles were ultrasonically granulated with a cell disruptor, and the mixture was preheated in a constant temperature water bath at 60°C for 3-5 min, and passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times respectively, and free tricholoma tricholoma active compound liposomes were removed by Sephadex G-50 column chromatography to obtain Saussurea involucrata active compound liposomes.

[0147] ADH-1 was added to the constructed Saussurea involucrata active compound liposomes and mixed evenly (20 ml of liposomes, 0.5-1 mg of ADH-1 (specific amount was 0.94 mg)), glutaraldehyde was slowly dripped to make the final concentration of glutaraldehyde reach 15 mM, ADH-1 was connected to the amino end of DSPE-PEG2000-NH2 on the surface of Saussurea involucrata active compound liposomes using glutaraldehyde as a linker, the mixture was incubated at room temperature for 5 min, and then placed in a dialysis bag (molecular weight 8000-14000), and dialyzed in PBS (pH 7.4) to remove unconnected ADH-1 and glutaraldehyde to obtain ADH-1 targeted liposomes.

[0148] (5) Preparation of coumarin 6-Saussurea involucrata functionalized nanocarriers

[0149] Weigh the prescribed amount of membrane material, Tianshan Saussurea active compound raw material (coarse hair ragweed) and TPGS (lecithin 37.5-40 mg, specifically 39.50 mg; β-sitosterol 10-12.5 mg, specifically 12.02 mg; distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG 2000 )1-2.5mg, specifically 2.46mg; Distearoylphosphatidylethanolamine-polyethylene glycol-amino (DSPE-PEG 2000 -NH2) 1-2.5 mg, specifically 2.50 mg; 8-12 mg, specifically 9.78 mg; 3-4 mg, specifically 3.28 mg, of TPGS were dissolved in an eggplant-shaped bottle with an appropriate amount of methanol, slowly vacuumed and rotated on a rotary evaporator at 39°C to form a film, 5 ml of 250 mM ammonium sulfate was added for ultrasonic hydration (ultrasonic conditions: power 60 W, time 10 min), and after complete hydration, the mixture was transferred to a 5 mL serum bottle, ultrasonically granulated with a cell disruptor, and preheated in a 60°C constant temperature water bath for 3-5 min, respectively, and passed through 0.4 μm and 0.2 μm polycarbonate membranes for 3 times each, and Sephadex G-50 column chromatography was used to remove free ragweed, an active compound of Saussurea involucrata, to obtain TPGS targeted liposomes.

[0150] ADH-1 was added to the constructed TPGS targeted liposomes and mixed evenly (20 ml of TPGS targeted liposomes, 0.5-1 mg of ADH-1 (specific dosage was 0.97 mg)), and glutaraldehyde was slowly dripped to make the final concentration of glutaraldehyde reach 15 mM. Glutaraldehyde was used as a linker to connect ADH-1 to the DSPE-PEG on the surface of the Tianshan Saussurea nanosystem. 2000-NH2, incubated at room temperature for 5 minutes, placed in a dialysis bag (molecular weight 8000-14000), dialyzed in PBS (pH 7.4) to remove unconnected ADH-1 and glutaraldehyde, and obtained Tianshan Saussurea functionalized liposomes.

[0151] The specific experimental steps are as follows:

[0152] A549 cells in the logarithmic growth phase and A549 cells after modeling were collected and cultured at 5×10 5 100 cells / well were inoculated in a 6-well plate. After culturing in a cell culture incubator for 24 h, free coumarin 6-ragweed (specifically, 3 μL of free ragweed solution, 3.3 μL of free coumarin 6 solution, and 493.7 μL of serum-free culture medium were added to obtain a solution with a final concentration of 2 μM of coumarin 6) and free coumarin 6 (specifically, 3.1 μL of free coumarin 6 liposomes were added to 446.9 μL of serum-free culture medium, The final concentration of coumarin 6 is 2 μM solution), coumarin 6-β-sitosterol liposomes (specifically: take 200 μL of β-sitosterol liposomes loaded with coumarin 6 to obtain a solution with a final concentration of coumarin 6 of 2 μM), coumarin 6-coarse-hairy ragweed-liposomes (specifically: take 73 μL of coarse-hairy ragweed liposomes loaded with coumarin 6 and add 377 μL of serum-free culture medium to obtain a solution with a final concentration of coumarin 6 of 2 μM), Coumarin 6-TPGS-coarse hairy ambrosia liposomes (specifically: 69 μL of TPGS-HIS liposomes loaded with coumarin 6 was added to 281 μL of serum-free medium to obtain a solution with a final concentration of coumarin 6 of 2 μM), coumarin 6-ADH-1-coarse hairy ambrosia liposomes (specifically: 113 μL of ADH-1-HIS liposomes loaded with coumarin 6 was added to 537 μL of serum-free medium to obtain a solution with a final concentration of coumarin 6 of 2 μM) and coumarin 6-tianshan snow lotus functionalized nanocarriers (specifically: 89 μL of ADH-1-TPGS-HIS liposomes loaded with coumarin 6 was added to 561 μL of serum-free medium to obtain a solution with a final concentration of coumarin 6 of 2 μM). The prepared dosage forms of a series of concentrations were added to the cell culture wells respectively, with serum-free medium as the control, and 3 replicate wells were set for each group. After administration, the cells were cultured for 2 h, and the cells were centrifuged and washed twice with pre-cooled PBS. The centrifuged cells were evenly blown with 500 μL of PBS and tested by flow cytometry. Figure 9-10. As can be seen from the figure, in the A549 cell uptake experiment, the Saussurea involucrata functionalized nanocarriers showed the strongest uptake ability of A549 cells, and there were different significant differences with other coumarin-loaded nanocarrier groups. In the A549 cells after modeling, the Saussurea involucrata functionalized nanocarriers also showed the strongest uptake ability of A549 cells, and there were significant differences with the coumarin-loaded nanocarrier groups. It should be noted that due to the lack of barriers in the in vitro cell uptake experiment, the uptake efficiency of the free coumarin 6 coumarin group (Free Cou+HIS) and the free coumarin 6 group (Free Cou) is stronger than that of the Saussurea involucrata functionalized nanocarriers loaded with coumarin 6, which is a normal phenomenon.

[0153] 5. Flow cytometry study on the effect of Saussurea involucrata functionalized nanosystem on inducing apoptosis of A549 cells

[0154] A549 cells in the logarithmic growth phase were collected and 5×10 5 Each well was inoculated in a 6-well plate and cultured in a 37°C, 5% CO2 incubator. After the cells grew for 24 hours, a series of concentrations of blank liposomes were prepared (specifically: 280 μL of blank liposomes were added to 420 μL of serum-free medium to obtain 40 μM, rough-haired ragweed free drug group (specifically: 7 μL of rough-haired ragweed was added to 693 μL of serum-free medium to obtain a 40 μM solution), HIS liposomes (specifically: 486 μL of rough-haired ragweed liposomes were added to 214 μL of serum-free medium to obtain a 40 μM solution), TPGS-HIS liposomes (specifically: 305 μL of TPGS-HIS liposomes were added to 195 μL of serum-free medium to obtain a 40 μM solution), ADH-1-HIS liposomes (specifically: 366 μL of ADH-1-HIS liposomes were added to 134 μL of serum-free medium to obtain a 40 μM solution), ADH-1-TPGS-HIS liposomes (specifically: take 304μL of ADH-1-TPGS-HIS liposomes and add 396μL of serum-free medium to obtain a 40μM solution). A series of blank liposomes, free drug of ragweed, liposomes of ragweed, TPGS-HIS liposomes, ADH-1-HIS liposomes and ADH-1-TPGS-HIS liposomes of prepared concentrations were added to the cell culture wells, with serum-free medium as the control, and 3 replicates were set up for each group. After continuing to culture in the incubator for 24h, rinse with cold PBS 3 times, digest with EDTA-free trypsin, centrifuge and wash the cells twice with PBS. Add 500μL of Binding Buffer, 5μL of Annexin V-PITC, and 10μL of PI, mix well, react for 5min at room temperature in the dark, and detect by flow cytometry.

[0155] Depend on Fig.11 It can be seen that different liposome groups have a slight apoptotic effect on A549 cells. After modifying the target head ADH-1 and TPGS, it can be clearly seen that the drug's ability to induce apoptosis of A549 cells is increased. The final dosage form group, i.e., the ADH-1-TPGS-HIS liposome group, has the highest apoptosis percentage of A549 cells, which is 43.77±11.26%.

[0156] 6. Scratch test

[0157] ① In the clean bench, use a marker pen to draw a horizontal line along the ruler on the back of each well of the 6-well plate.

[0158] ② Take cells in the logarithmic growth phase, 7×10 5 After inoculating into each well of a 6-well plate, the cells were cultured in an incubator for 24 h to allow the cells to cover the bottom of the well.

[0159] ③ Place a 200μL pipette tip perpendicular to the bottom of the 6-well plate and scratch along the horizontal line on the back. Gently wash with sterile PBS three times to wash away the detached cells and carefully wipe the horizontal line on the back.

[0160] ④ Use incomplete culture medium containing 0.5% FBS to prepare a series of concentrations of blank liposomes (specifically: take 280 μL of blank liposomes and add 420 μL of serum-free culture medium to obtain 40 μM), rough-haired ragweed free drug group (specifically: take 8 μL of rough-haired ragweed and add 792 μL of serum-free culture medium to obtain a 40 μM solution), rough-haired ragweed liposomes (specifically: take 529 μL of rough-haired ragweed liposomes and add 107 μL of serum-free culture medium to obtain a 40 μM solution), TPGS-HIS liposomes (specifically: 260 μL of TPGS-HIS liposomes per well to obtain a 40 μM solution), ADH-1-HIS liposomes (specifically: take 232 μL of ADH-1-HIS liposomes per well to obtain a 40 μM solution), ADH-1-TPGS-HIS Liposomes (specifically: take 516 μL of ADH-1-TPGS-HIS liposomes and add 184 μL of serum-free culture medium to obtain a 40 μM solution). A series of prepared blank liposomes, free drug of ragweed, liposomes of ragweed, TPGS-HIS liposomes, ADH-1-HIS liposomes and ADH-1-TPGS-HIS liposomes were added to the cell culture wells, and the drug-containing culture medium was added at 2 mL / well. The control group was only added with an incomplete culture medium containing 0.5% FBS, and the culture was continued for 24 hours.

[0161] ⑤Take samples and take photos (×5 magnification) and compare the differences in scratch width among the groups.

[0162] Results Fig.12From the experimental results, it can be seen that the migration of the modeling group without drug administration was the most obvious, and the blank group also showed migration. The migration of the other drug-loaded dosage forms was not very obvious, indicating that each dosage form group played a good role in inhibiting the migration of A549 cells.

[0163] 7. Transwell experiment

[0164] (1) A549 cells were passaged according to normal procedures, divided into 2-3 new culture flasks, and placed in an incubator for overnight incubation to allow them to adhere to the wall and grow. After 12 hours of serum-free culture, TGF-β1 was added to the modeling group to a final concentration of 10 ng / mL, and the control group was added with an equal amount of serum-free culture medium and placed in an incubator at 37°C and 5% CO2 for 48 hours.

[0165] (2) Matrigel was placed at 4°C overnight to allow it to melt and become liquid; Matrigel was diluted with 4°C pre-cooled serum-free medium at a ratio of 1:8 (to a final concentration of 1 mg / mL) and mixed (operated on ice). 100 μL of the diluted Matrigel was added vertically to the center of the bottom of the upper chamber, placed in a 37°C incubator, and incubated for 4-5 hours to dry into a gel.

[0166] (3) Collect the cells, resuspend them in serum-free medium, count them, and adjust the cell number to 2×10 5, prepare a cell suspension; wash Matrigel once with serum-free medium; add 100 μL of cell suspension to the upper chamber, and then add the prepared drugs of each dosage form group (specifically: prepare a series of concentrations of blank liposomes (specifically: take 24 μL of blank liposomes and add 276 μL of serum-free medium to obtain 40 μM, rough-haired ragweed free drug group (specifically: take 1.2 μL of rough-haired ragweed and add 598.8 μL of serum-free medium to obtain a 40 μM solution), rough-haired ragweed liposomes (specifically: take 46 μL of rough-haired ragweed liposomes and add 254 μL of serum-free medium to obtain a 40 μM solution), TPGS-HIS liposomes (specifically: 77 μL of TPGS-HIS liposomes and add 277 μL of serum-free medium to obtain a 40 μM solution), ADH-1-HIS Liposomes (specifically: take 69 μL of ADH-1-HIS liposomes and add 231 μL of serum-free medium to obtain a 40 μM solution), ADH-1-TPGS-HIS liposomes (specifically: take 44 μL of ADH-1-TPGS-HIS liposomes and add 256 μL of serum-free medium to obtain a 40 μM solution). And the prepared series of concentrations of blank liposomes, free drug of ragweed, ragweed liposomes, TPGS-HIS liposomes, ADH-1-HIS liposomes and ADH-1-TPGS-HIS liposomes were added to the cell culture wells respectively, and the corresponding solvent was added as a control, so that they were finally grouped into: control group, modeling group and post-modeling drug administration group, among which the post-modeling drug administration group was further divided into free ragweed group, blank liposomes, HIS liposomes, TPGS-HIS liposomes, ADH-1-HIS liposomes and ADH-1-TPGS-HIS liposomes.

[0167] (4) Add 500 μL of conditioned medium containing 20% ​​FBS to the lower chamber; incubate in a 37°C incubator for 24-48 h; remove the transwell chamber, dry the upper chamber liquid, wash twice with PBS, fix with 4% paraformaldehyde at room temperature for 30 min, wash twice with PBS, add crystal violet (0.1%) to stain for 30 min, wash twice with PBS, carefully wipe the cells on the upper chamber surface with a cotton ball, randomly select 5 fields of view under a microscope, take pictures and count, take the average value, and calculate the number of migrated cells. Set up 3 replicate wells in parallel for each group.

[0168] The results are as follows Fig.13 , 14, 15. From the experimental results, it can be seen that after 24 hours of TGF-β1 modeling, the number of cells entering the lower chamber was significantly more than that of the non-modeling group, and the modeling group after 48 hours of TGF-β1 action was also significantly more than that of the non-modeling group, indicating that the invasion ability of A549 cells can be enhanced after induction by TGF-β1, suggesting that the epithelial-mesenchymal transition model of A549 cells was successfully established. In addition, the results showed that the Tianshan Saussurea functionalized nanocarrier group significantly reduced the number of A549 lung cancer cells that passed through the chamber, and had the strongest ability to inhibit the invasion of A549 lung cancer cells.

[0169] 8. Western blot experiment

[0170] After modeling, A549 cells were collected and 5×10 5 / well in a 6-well plate, prepare a series of concentrations of blank liposomes (specifically, take 280 μL of blank liposomes and add 420 μL of serum-free culture medium to obtain a 40 μM solution), rough-haired ragweed free drug group (specifically, take 7 μL of rough-haired ragweed and add 693 μL of serum-free culture medium to obtain a 40 μM solution), HIS liposomes (specifically, take 486 μL of rough-haired ragweed liposomes and add 214 μL of serum-free culture medium to obtain a 40 μM solution), TPGS-HIS liposomes (specifically, take 305 μL of TPGS-HIS liposomes and add 195 μL of serum-free culture medium to obtain a 40 μM solution), ADH-1-HIS liposomes (specifically, take 366 μL of ADH-1-HIS liposomes and add 134 μL of serum-free culture medium to obtain a 40 μM solution), ADH-1-TPGS-HIS liposomes (specifically, take ADH-1-TPGS-HIS 304 μL of liposomes plus 396 μL of serum-free medium will give a 40 μM solution). After the cells are basically full, the drug is administered. A series of blank liposomes, free drug of ragweed, ragweed liposomes, TPGS-HIS liposomes, ADH-1-HIS liposomes and ADH-1-TPGS-HIS liposomes of prepared concentrations are added to the cell culture wells, respectively. Serum-free medium is used as a control, and 3 replicate wells are set up in each group. After incubation for 24 hours, total protein is extracted. After electrophoresis transfer, each sample is blocked with 5% skim milk powder for 1 hour, the membrane is washed and incubated with the primary antibody at 4°C overnight. The primary antibody is E-cadherin, vimentin, N-cadherin, Akt, p-Akt, Caspase-9 and BAD were diluted at 1:20000, 1:1000, 1:20000, 1:1000, 1:1000, 1:2000 and 1:2500, respectively. After washing with TBST, the secondary antibody was incubated at room temperature for 2 hours, and the membrane was washed again for chemiluminescence. The gray value of each band was analyzed using Image J software, with β-actin as an internal reference.

[0171] The results of the regulation of E-cadherin, N-cadherin and Vimentin proteins in A549 cells by ragweed extract and its preparations are shown in Figure 2. Fig.16 shown.

[0172] The results showed that compared with the control group, the TGF-β1 group could upregulate the levels of Vimentin and N-cadherin proteins and inhibit the expression of E-cadherin, indicating that the epithelial-mesenchymal transition model of A549 cells was successfully established at the protein level. In addition, after administration of different groups of preparations, the levels of Vimentin and N-cadherin proteins showed a downward trend, among which the Tianshan Saussurea functionalized nanocarrier group had the most significant downward effect; the expression level of E-cadherin showed an increasing trend, among which the Tianshan Saussurea functionalized nanocarrier group had the most significant upward effect, indicating that the prepared Tianshan Saussurea functionalized nanocarrier had the best inhibitory effect on the invasion and migration of lung cancer cells caused by epithelial-mesenchymal transition.

Claims

1. A targeted liposome, comprising a liposome containing TPGS and ADH-1; the ADH-1 is connected to the amino group of the liposome; The TPGS-containing liposome is prepared from lecithin, β-sitosterol, distearoylphosphatidylethanolamine-polyethylene glycol, distearoylphosphatidylethanolamine-polyethylene glycol-amino and TPGS; wherein, The amino group of the TPGS-containing liposome is provided by distearoylphosphatidylethanolamine-polyethylene glycol-amino group; The mass ratio of ADH-1 to the TPGS-containing liposome is 1:10-25; the mass ratio refers to the ratio of the mass of ADH-1 input to the sum of the mass of lecithin, β-sitosterol, distearoylphosphatidylethanolamine-polyethylene glycol, distearoylphosphatidylethanolamine-polyethylene glycol-amino and TPGS input for preparing the TPGS-containing liposome; In the TPGS-containing liposome, the weight proportions of the raw materials are: 37.5-40 parts of lecithin, 10-12.5 parts of β-sitosterol, 1-2.5 parts of distearoylphosphatidylethanolamine-polyethylene glycol, 1-2.5 parts of distearoylphosphatidylethanolamine-polyethylene glycol-amino, and 3-4 parts of TPGS; The mass ratio of lecithin to β-sitosterol is 3:

1.

2. The method for preparing the targeted liposome according to claim 1, comprising the steps of: 1) Preparation of TPGS-containing liposomes: The lecithin, the β-sitosterol, the distearoylphosphatidylethanolamine-polyethylene glycol, the distearoylphosphatidylethanolamine-polyethylene glycol-amino and the TPGS are prepared by a thin film dispersion method to obtain TPGS-containing liposomes; 2) Using glutaraldehyde as a linker, the ADH-1 is linked to the amino group of the TPGS-containing liposome to obtain the targeted liposome.

3. The preparation method according to claim 2, characterized in that: In the step 1), the thin film dispersion method specifically comprises the following steps: dissolving the lecithin, the β-sitosterol, the distearoylphosphatidylethanolamine-polyethylene glycol, the distearoylphosphatidylethanolamine-polyethylene glycol-amino and the TPGS in an organic solvent, performing rotary evaporation under reduced pressure to remove the organic reagent, then adding a hydration medium, ultrasonically hydrating, and membrane filtering to obtain liposomes containing TPGS.

4. The preparation method according to claim 3, characterized in that: In the step 1), the organic solvent is methanol; the hydration medium is 250 mM ammonium sulfate solution; The membrane filtration refers to passing through 0.4 μm and 0.2 μm polycarbonate membranes three times respectively; The specific method of step 2) is as follows: the ADH-1 and the TPGS-containing liposomes are mixed evenly, glutaraldehyde is slowly dripped into the mixture to make the final concentration of glutaraldehyde reach 12-18 mM; glutaraldehyde is used as a linker to connect ADH-1 to the DSPE-PEG on the surface of the TPGS-containing liposomes. 2000 The liposomes were connected to the amino terminus of -NH2, incubated at room temperature for 5 min, placed in a dialysis bag, and dialyzed in a PBS buffer solution at pH 7.4 to remove unconnected ADH-1 and glutaraldehyde to obtain targeted liposomes.

5. A targeted drug-loaded liposome obtained by encapsulating the drug in the targeted liposome according to claim 1; The drug is ragweed; The drug-lipid ratio of the drug-loaded liposome is 1:4-6.

6. The targeted drug-loaded liposome according to claim 5, characterized in that: The drug-lipid ratio of the drug-loaded liposome is 1:

5.

7. The method for preparing the targeted drug-loaded liposome according to claim 5 or 6, comprising the following steps: a) Preparation of drug-loaded liposomes containing TPGS: The lecithin, the β-sitosterol, the distearoylphosphatidylethanolamine-polyethylene glycol, the distearoylphosphatidylethanolamine-polyethylene glycol-amino, the TPGS and the drug are prepared by a thin film dispersion method to obtain a drug-loaded liposome containing TPGS; b) Using glutaraldehyde as a linker, the ADH-1 is linked to the amino group of the drug-loaded liposome containing TPGS, thereby obtaining the targeted drug-loaded liposome.

8. Use of the drug-loaded liposome according to claim 5 or 6 in any one of the following 1) to 7): 1) Preparation of drugs for preventing and / or treating tumors; 2) Preparation of drugs for preventing and / or treating tumor metastasis; 3) Preparation of agents for inhibiting the proliferation of eukaryotic tumor cells; 4) Preparation of reagents that promote apoptosis of eukaryotic tumor cells; 5) Preparation of agents for inhibiting the migration of eukaryotic tumor cells; 6) Prepare agents for inhibiting epithelial-mesenchymal transition in non-small cell lung cancer; 7) Preparation of agents that enhance the drug uptake ability of eukaryotic tumor cells; The tumor is lung cancer; The tumor cells are lung cancer cells.

9. The use according to claim 8, characterized in that: The eukaryotic organism is a human or a mammal.

10. The use according to claim 9, characterized in that: The lung cancer is non-small cell lung cancer; The lung cancer cells are A549 lung adenocarcinoma cells.

11. The use according to claim 10, characterized in that: The lung cancer is lung adenocarcinoma.

Citation Information

Patent Citations

  • Functional lipidosome for treating brain tumor and preparing method and application thereof

    CN105853360A

  • Functional liposome for treating lung cancer as well a s preparation method and application of functional liposome

    CN107432875A